The U.S. Food and Drug Administration announced a consolidation of its patchwork adverse-event reporting systems into a single Adverse Event Monitoring System. Agency statements and reporting indicate the platform will eventually unify vaccine and drug safety trackers and enable more real-time surveillance across centers. FDA officials said the move aims to modernize signal detection, reduce fragmentation across reporting portals, and improve regulators’ ability to analyze and act on safety data. The change affects manufacturers, healthcare providers and public reporting routes and will require technical and procedural updates from stakeholders. Clarification: Adverse event reporting aggregations collect post-market safety reports from clinicians, patients, and manufacturers that regulators use to detect safety signals and trigger reviews, labeling changes, or recalls.